APOLLOX
Live / Registered — Registered (as of 21 Oct 2025)
What this means for you
Registered since 21 Oct 2025. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 79411378
- Registration number
- 7989067
- Mark type
- Stylized text
- Filed
- 28 Aug 2024
- Published for opposition
- 02 Sept 2025
- Registered
- 21 Oct 2025
- Attorney of record
- Allisen Pawlenty
Goods and services
- Class 001 — Chemicals: Cell cultures used in industry and science; mammalian cell cultures and vectors, being independent replicating pieces of DNA that can transfer DNA sequences, each for use in industry and science; biological preparations for use in science; biological preparations for use in cell cultures for use in industry and science; cell culture reagents for scientific and research use; media for cell culture for use in industry and science; chemicals for use in biotechnological product development; chemicals for use in biotechnological manufacturing processes
- Class 040 — Treatment of materials: Processing and manufacturing of vectors, cell cultures and recombinant proteins for use in biotechnology industries to the order and specification of others; manufacture, processing and production of recombinant proteins for use in the biotechnology industries to the order and specification of others; custom processing and manufacturing of pharmaceuticals; custom processing and manufacturing of biological products; custom manufacture of biopharmaceuticals; cell culture manufacturing services for others; custom manufacture of biologics; information, advice and consultancy in relation to all the aforesaid
- Class 042 — Scientific and technological services: Scientific research, industrial research in the field of biomanufacturing, bioprocessing, pharmaceuticals and biopharmaceuticals and technical product research and development services in the field of biomanufacturing, bioprocessing, pharmaceuticals and biopharmaceuticals; development and analysis services relating to the use of mammalian cell cultures and vectors in the field of biotechnology; industrial process development in the field of biomanufacturing, bioprocessing, pharmaceuticals and biopharmaceuticals; development of processes for the use of mammalian cell cultures and vectors in the manufacture of biotechnology products; technical project studies in the field of biomanufacturing, bioprocessing, pharmaceuticals and biopharmaceuticals; technical project studies relating to the use of mammalian cell cultures and vectors in the field of biotechnology; development of processes for the use in the manufacture of biotechnology products; biotechnology product testing services; research and consultancy in the field of biotechnology; research and development in the pharmaceutical and biotechnology industry; development of processes for use in the manufacture of pharmaceutical and biological products; biopharmaceutical product development; design and development of manufacturing processes in the field of biopharmaceuticals; development of chemicals for use in the manufacture of biotechnology products and pharmaceuticals; preparation of biological samples for analysis in research laboratories; information, advice and consultancy in relation to all the aforesaid
Owner
Prosecution history
- 21 Jan 2026 — FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
- 29 Nov 2025 — NEW REPRESENTATIVE AT IB RECEIVED
- 21 Oct 2025 — NOTICE OF REGISTRATION CONFIRMATION EMAILED
- 21 Oct 2025 — REGISTERED-PRINCIPAL REGISTER
- 02 Sept 2025 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
- 02 Sept 2025 — PUBLISHED FOR OPPOSITION
- 27 Aug 2025 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
- 31 Jul 2025 — APPROVED FOR PUB - PRINCIPAL REGISTER
- 31 Jul 2025 — EXAMINER'S AMENDMENT ENTERED
- 31 Jul 2025 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
- 31 Jul 2025 — EXAMINERS AMENDMENT E-MAILED
- 31 Jul 2025 — EXAMINERS AMENDMENT -WRITTEN
- 16 Jul 2025 — TEAS/EMAIL CORRESPONDENCE ENTERED
- 16 Jul 2025 — CORRESPONDENCE RECEIVED IN LAW OFFICE
- 16 Jul 2025 — TEAS RESPONSE TO OFFICE ACTION RECEIVED